Overview

Ranibizumab in Patients With Branch Retinal Vein Occlusion

Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
In a recent study we could show that the early retinal venous vasoconstriction after grid photocoagulation in branch retinal vein occlusion (BRVO) is closely correlated to the visual outcome after three months. This could be of clinical importance, because the degree of vasoconstriction might be an early marker of treatment success, compatible with the idea that hypoxia is the major trigger of VEGF in BRVO. The present study evaluates the response of retinal vessel diameters to anti VEGF treatment with lucentis in patients with BRVO. This is done in an effort to gain insight into the retinal hemodynamic consequences of anti VEGF treatment in BRVO. The hypothesis that anti VEGF treatment is associated with a vasoconstrictor response in retinal vessel in patients with BRVO is tested.
Phase:
Phase 4
Details
Lead Sponsor:
Medical University of Vienna
Treatments:
Endothelial Growth Factors
Ranibizumab